Thermo Fisher Scientific is finally starting to show signs of growth after getting through the headwind of declining covid-related business. Growth sources include increased business in China, completion of the Olink deal, and an increase in the number of clinical trials. Financial model updates and valuation analysis suggest the stock is currently priced at fair value, making it a Hold for now.
The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.
The headline numbers for Thermo Fisher (TMO) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Thermo Fisher Scientific (TMO) reported better second-quarter earnings than analysts had expected Wednesday, and also raised its projections for the full fiscal year.
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.37 per share, beating the Zacks Consensus Estimate of $5.13 per share. This compares to earnings of $5.15 per share a year ago.
Thermo Fisher on Wednesday raised its annual profit outlook and posted a better-than-expected second-quarter profit, banking on improved demand for its tools and services used in clinical trials.
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength in Analytical Instrument and Laboratory Products and Services segments is likely to have driven Thermo Fisher's (TMO) second-quarter 2024 performance.
Stocks tend to sell off after they reach resistance. They also tend to rally off of support.
Thermo Fisher (TMO) announces a partnership with the National Cancer Institute for the myeloMATCH precision medicine umbrella trial to fuel research regarding new treatments for AML and MDS.
Investors with an interest in Medical - Instruments stocks have likely encountered both Thermo Fisher Scientific (TMO) and Idexx Laboratories (IDXX). But which of these two stocks is more attractive to value investors?
Thermo Fisher (TMO) announces the opening of NanoPort, the company???s first electron microscopy demo center in Taiwan, strategically located in the region?